Sansure Biotech receives China registration for a liver cancer diagnostic kit
November 13, 2026
Source: drugdu
21
Sansure Biotech (688289.SH) reported that China’s National Medical Products Administration had issued a medical device registration certificate for its human OTX1, MTHFD2 and FAR1 gene methylation assay. The fluorescence probe PCR kit qualitatively detects methylation of these genes in peripheral blood plasma to aid diagnosis in people at high risk of primary hepatocellular carcinoma.
Source: http://finance.eastmoney.com/a/202611123929773912.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- GSK’s application for marketing approval in China for its recombinant herpes zoster vaccine pre-filled syringe formulation has been accepted. November 13, 2026
- Novo Nordisk has submitted an application for marketing approval in China for its once-weekly subcutaneous injection of CagriSema, for long-term weight management. November 13, 2026
- Colombia’s INVIMA approves Sinotherapeutics’ generic posaconazole delayed-release tablets November 13, 2026
- Baheal renames itself as it expands into drug development and manufacturing November 13, 2026
- Everest Medicines receives China approval for 100 mg eravacycline injection November 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
